The role of dihydrotestosterone in benign prostatic hyperplasia (Q44376212)

2 December 2017

The role of dihydrotestosterone in benign prostatic hyperplasia (English)

1 reference

2 December 2017

Culley Carson

1

1 reference

PubMed ID

12657354

2 December 2017

Roger Rittmaster

series ordinal

2

1 reference

PubMed ID

12657354

2 December 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

2 December 2017

1 reference

2 December 2017

61

1 reference

2 December 2017

4 Suppl 1

1 reference

2 December 2017

2-7

1 reference

The development of human benign prostatic hyperplasia with age

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Endocrine and adrenergic pharmacological intervention in diseases of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Androgen receptor signalling in the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Pathology of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

The role of 5alpha-reduction in steroid hormone physiology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Antagonistic effect of androgen on prostatic cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Proliferation and differentiation of prostatic stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2803%2900045-1

7 January 2021

10.1016/S0090-4295(03)00045-1

Identifiers

DOI

1 reference

2 December 2017

1 reference

PubMed ID

12657354